Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) insider Mark James Litton sold 16,519 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $10.80, for a total transaction of $178,405.20. Following the sale, the insider now owns 116,451 shares in the company, valued at $1,257,670.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Mark James Litton also recently made the following trade(s):

  • On Monday, October 16th, Mark James Litton sold 16,520 shares of Alder BioPharmaceuticals stock. The stock was sold at an average price of $12.33, for a total transaction of $203,691.60.

Shares of Alder BioPharmaceuticals, Inc. (NASDAQ ALDR) traded down $0.05 during midday trading on Friday, reaching $10.60. 851,772 shares of the company were exchanged, compared to its average volume of 1,140,821. Alder BioPharmaceuticals, Inc. has a 1-year low of $8.60 and a 1-year high of $29.30.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.29. During the same quarter in the prior year, the business posted ($0.70) earnings per share. equities analysts expect that Alder BioPharmaceuticals, Inc. will post -5.36 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Alder BioPharmaceuticals, Inc. (ALDR) Insider Mark James Litton Sells 16,519 Shares of Stock” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/18/alder-biopharmaceuticals-inc-aldr-insider-mark-james-litton-sells-16519-shares-of-stock.html.

ALDR has been the topic of a number of analyst reports. ValuEngine upgraded shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 30th. Mizuho reissued a “buy” rating and issued a $32.00 target price on shares of Alder BioPharmaceuticals in a report on Wednesday, November 8th. Cowen and Company began coverage on shares of Alder BioPharmaceuticals in a report on Tuesday, September 26th. They issued an “outperform” rating and a $20.00 target price for the company. Royal Bank Of Canada began coverage on shares of Alder BioPharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $17.00 target price for the company. Finally, Canaccord Genuity began coverage on shares of Alder BioPharmaceuticals in a report on Thursday, October 26th. They issued a “buy” rating and a $20.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $28.07.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC raised its holdings in Alder BioPharmaceuticals by 611.7% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 23,373 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 20,089 shares during the last quarter. Jane Street Group LLC bought a new position in Alder BioPharmaceuticals in the 3rd quarter valued at approximately $184,000. Cornerstone Capital Management Holdings LLC. raised its holdings in Alder BioPharmaceuticals by 23.3% in the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 37,620 shares of the biopharmaceutical company’s stock valued at $459,000 after buying an additional 7,100 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in Alder BioPharmaceuticals in the 3rd quarter valued at approximately $752,000. Finally, California State Teachers Retirement System raised its holdings in Alder BioPharmaceuticals by 21.3% in the 3rd quarter. California State Teachers Retirement System now owns 101,381 shares of the biopharmaceutical company’s stock valued at $1,242,000 after buying an additional 17,790 shares during the last quarter. Institutional investors and hedge funds own 78.93% of the company’s stock.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Insider Buying and Selling by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.